These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31036088)

  • 1. A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
    Li C; Wang X; Wang X; Han C; Wang P; Pang Q; Chen J; Sun X; Wang L; Zhang W; Lin Y; Ge X; Zhou Z; Ni W; Chang X; Liang J; Deng L; Wang W; Zhao Y; Xiao Z
    BMC Cancer; 2019 Apr; 19(1):397. PubMed ID: 31036088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
    Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
    BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction.
    Yaremko BP; Palma DA; Erickson AL; Pierce G; Malthaner RA; Inculet RI; Dar AR; Rodrigues GB; Yu E
    Radiat Oncol; 2013 Feb; 8():33. PubMed ID: 23398690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial.
    Welsh JW; Seyedin SN; Allen PK; Hofstetter WL; Ajani JA; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Nguyen QN; Minsky BD; Erasmus JJ; Lee JH; Bhutani M; Komaki RU
    J Thorac Oncol; 2017 Feb; 12(2):375-382. PubMed ID: 27794500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined taxane-based chemotherapy and intensity-modulated radiotherapy with simultaneous integrated boost for gastroesophageal junction adenocarcinoma.
    Spatola C; Tocco A; Pagana A; Milazzotto R; Luigi R; Salamone V; Militello C; Migliore M; Foti PV; Cataldo AD; Acquaviva G; Privitera G
    Future Oncol; 2018 Mar; 14(6s):47-51. PubMed ID: 29664354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.
    Chen D; Menon H; Verma V; Seyedin SN; Ajani JA; Hofstetter WL; Nguyen QN; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Barsoumian HB; Erasmus JJ; Lee JH; Bhutani MS; Hess KR; Minsky BD; Welsh JW
    JAMA Oncol; 2019 Nov; 5(11):1597-1604. PubMed ID: 31529018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG).
    Shen J; Zhu X; Du Y; Zhu Y; Yu P; Yang L; Xu Z; Huang L; Zhang Y; Zhang Y; Liu L; Cheng X
    Trials; 2021 Oct; 22(1):753. PubMed ID: 34717717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial.
    Wen Y; Zhao Z; Miao J; Yang Q; Gui Y; Sun M; Tian H; Jia Q; Liao D; Yang C; Du X
    Medicine (Baltimore); 2017 Dec; 96(49):e8998. PubMed ID: 29245275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
    Lertbutsayanukul C; Kitpanit S; Kannarunimit D; Chakkabat C; Oonsiri S; Thephamongkhol K; Puataweepong P; Katanyoo K; Sukhaboon J; Tovanabut C; Chongsathientham S; Treeratsapanich P; Soonthornrak J; Prayongrat A
    Trials; 2022 Oct; 23(1):897. PubMed ID: 36273186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.
    Adelstein DJ; Rice TW; Rybicki LA; Saxton JP; Videtic GM; Murthy SC; Mason DP; Rodriguez CP; Ives DI
    J Thorac Oncol; 2009 Oct; 4(10):1264-9. PubMed ID: 19668013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of adenocarcinoma of the esophagogastric junction successfully treated with chemoradiation therapy].
    Ebisui C; Okada K; Nishigaki T; Owada Y; Nagase H; Mukai R; Momozane T; Murakami M; Ide Y; Yanagisawa T; Murata K; Yokouchi H; Tamai M; Kinuta M
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2143-5. PubMed ID: 22202310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
    Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
    Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroesophageal junction adenocarcinoma.
    Swisher SG; Pisters PW; Komaki R; Lahoti S; Ajani JA
    Curr Treat Options Oncol; 2000 Dec; 1(5):387-98. PubMed ID: 12057146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
    von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M
    Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
    Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
    BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
    Modesto A; Dalmasso C; Lusque A; Vieillevigne L; Izar F; Moyal E; Carrère N; Guimbaud R; Rives M
    Cancer Radiother; 2020 Apr; 24(2):88-92. PubMed ID: 32156457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
    Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
    BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer.
    Li C; Ni W; Wang X; Zhou Z; Deng W; Chang X; Chen D; Feng Q; Liang J; Wang X; Deng L; Wang W; Bi N; Zhang T; Xiao Z
    Radiat Oncol; 2019 Mar; 14(1):48. PubMed ID: 30876442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.